Search

Search Constraints

You searched for: Author/Creator Pollock, Carol

Search Results

2. Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. (16th November 2022)

3. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Issue 10184 (11th May 2019)

4. Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial. Issue 18 (8th February 2021)

5. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial. Issue 9 (27th August 2019)

6. Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32, 057 participants from six prospective studies. Issue 1 (December 2016)

8. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. Issue 11 (November 2020)

9. Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial. Issue 5 (6th February 2023)

10. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. (23rd August 2021)